Navigation Links
Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
Date:5/7/2012

acted as the exclusive advisor to Coherus BioSciences in this licensing partnership with Daiichi Sankyo.

About Coherus BioSciences

Coherus BioSciences is an emerging biopharmaceutical company headquartered in the San Francisco Bay Area with an entirely new model for developing safe, high-quality biosimilar therapeutics.  Founded in 2010, Coherus already has formed global partnerships with top tier pharma and filled the pipeline with five product candidates focused on treating oncology and inflammatory diseases.  Led by a group of early biotech pioneers, Coherus has reinvented the entire business of developing biologic medicines, from concept to commercialization, so that more patients around the world can have greater access to quality therapeutics. For additional information, please visit www.coherus.com.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

Contact: Maureen Lopez
Coherus BioSciences
Phone Number 1-800-794-5434

Media contact for Daiichi Sankyo Co. Ltd.: +81-3-6225-1126


'/>"/>
SOURCE Coherus BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
2. Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
3. DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical™ for Pan-European Systolic Hypertension Study
4. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
5. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
6. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
8. Milestone Biosciences, LLC Further Strengthens Executive Management Team
9. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
10. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
11. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
(Date:7/24/2014)... balances – 4 steps – One Recommendation: the web-based ... narrows down the mass of product choices to a ... , First, select the working environment, then enter the ... define the accuracy – it’s really that simple. Specifying ... to models that fit best with the customer’s industry ...
(Date:7/24/2014)... 2014 As part of the long-term ... the MENA region during 2014 with potential global expansion. ... agreement with DZS to manage our clinical trials globally ... VP of R&D and President of SBI pharmaceuticals MENA, ... practices with a focus on utilizing eClinical software and ...
(Date:7/23/2014)... Heroic worldwide conservation efforts have made great strides in ... in China, there are over 65 giant panda reserves ... But despite these efforts, just 1596 pandas remain in ... and zoos hope to save the panda by improving ... to the wild. Just how are these high-profile programs ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... , THE WOODLANDS, Texas, Sept. 9 ... company focused on discovering and developing breakthrough treatments for human disease, announced ... president and chief executive officer, will present at the Morgan Stanley Global ... York on Tuesday, September 15, 2009 at 1:35 p.m. Eastern Time. ...
... ... software makes its debut at leading industry conferences. , ... Cambridge, MA (PRWEB) September 9, 2009 -- Akaza Research, the leading ... flagship product, OpenClinica, at two major industry conferences this fall. , , ,Representatives from Akaza ...
... Ontario, Sept. 8 Helix BioPharma Corp. (TSX, FSE: "HBP"; OTCQX: "HXBPF") ... 6,625,000 units at $2.05 per unit. , , ... purchase warrant, with each common share purchase warrant entitling the holder to ... price of $2.87 for up to three years after the closing date ...
Cached Biology Technology:Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Akaza Research to Present OpenClinica 3.0 at Upcoming Clinical Research Conferences: SoCRA, SCDM 2Helix BioPharma Closes Private Placement 2Helix BioPharma Closes Private Placement 3
(Date:7/24/2014)... reduce fire hazard in the United States, wildland managers ... shrubs and suppressed trees (ladder fuels). These cuttings ... of low fire danger in order to dispose of ... air pollutants, managers often cover all or part of ... to as agricultural plastic, in order to keep water ...
(Date:7/24/2014)... which life arose have been maintained in our cells today ... Research published today in the Journal of Biological Chemistry ... also in animals still perform ancient reactions thought to have ... billion years ago. , The primordial soup theory suggests that ... of the combination of metals, gases from the atmosphere and ...
(Date:7/24/2014)... Expanding on his work with a new drug that successfully ... of Houston has received a $250,000 grant to expand his ... effort to treat a wider range of autoimmune diseases., Chandra ... biomedical Engineering at UH, previously published a study in Arthritis ... that successfully treated lupus in mice and reduced the number ...
Breaking Biology News(10 mins):Study gives new perspective on agricultural plastic, debris burning, and air quality 2Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3
... and technical publishing business of John Wiley & Sons, Inc. ... Taipei have signed an agreement to closely cooperate and jointly ... The journal will be available online from volume 2011 in ... collections of online resources, used by 10 million people a ...
... Drying of northern wetlands has led to much more severe ... the atmosphere, according to new research led by a University ... Nature Communications , is the first to investigate the effect ... vulnerability of that carbon to burning. "Russia, Indonesia and ...
... by Dr. Jayne S. Weiss, Professor and Chair of Ophthalmology ... found that a defect in a gene involved in a ... of invasive bladder cancer. The findings are published in the ... Cell Biology . It is the featured research of the ...
Cached Biology News:Journal of the Chinese Chemical Society expands international reach with Wiley-VCH 2Drying intensifying wildfires, carbon release ninefold, study finds 2Mutation in gene associated with rare eye disease also contributes to bladder cancer growth 2
G-protein coupled purinergic receptor P2Y8...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Biology Products: